Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evonail for Docetaxel-Induced Onycholysis in Breast Cancer
NCT02670603Completed
- Sponsor
- Samsung Medical Center
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of efinaconazole in onycholysis (2 arms), sponsored by Samsung Medical Center. Primary endpoint: The incidence of onycholysis Grade 2 or more at 12 weeks. Started Aug 2015; status: completed.
02
Drugs
efinaconazole
03
Conditions
onycholysis
Beyond the preview
Go deeper on NCT02670603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670603.